




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C12N 15/12, 15/63, 5/16, C07K 13/00	A1	(11) International Publication Number: WO 94/28131 (43) International Publication Date: 8 December 1994 (08.12.94)
(21) International Application Number: PCT/US94/05666 (22) International Filing Date: 20 May 1994 (20.05.94)	(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/066,371 21 May 1993 (21.05.93) US	Published With international search report.	
<p>(71) Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; Mail Code 305-6, 1201 East California, Pasadena, CA 91125 (US).</p> <p>(72) Inventors: LESTER, Henry, A.; 1610 Bushnell, South Pasadena, CA 91030 (US). DASCAL, Nathan; 1720 LaSenda Place, South Pasadena, CA 91030 (US). LIM, Nancy, F.; 866 North Chester, Pasadena, CA 91106 (US). SCHREIBMAYER, Wolfgang; 1720 LaSenda Place, South Pasadena, CA 91030 (US). DAVIDSON, Norman; 318 East Laurel, Sierra Madre, CA 91024 (US).</p> <p>(74) Agents: TRECARTIN, Richard, F. et al.; Flehr, Hohbach, Test, Albritton &amp; Herbert, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).</p>		

(54) Title: DNA ENCODING INWARD RECTIFIER, G-PROTEIN ACTIVATED, MAMMALIAN, POTASSIUM KGA CHANNEL AND USES THEREOF



## (57) Abstract

Isolated nucleic acid molecules which encode inward rectifier, G-protein activated, mammalian potassium KGA channels are disclosed. Also provided are related nucleic acid probes, vectors, and recombinant expression systems for the KGA potassium channels.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

DNA ENCODING INWARD RECTIFIER, G-PROTEIN  
ACTIVATED, MAMMALIAN, POTASSIUM KGA CHANNEL  
AND USES THEREOF

The invention disclosed herein was made with U.S. Government  
5 support under USPHS grants GM29836 and MH49176. Accordingly,  
the the U.S. government has certain rights in this  
invention.

Background of the Invention

10 Throughout this application various publications are  
referenced by their reference number within parentheses.  
Full citations for these publications may be found at the  
end of the specification immediately preceding the sequence  
listing. The disclosures of these publications in their  
15 entireties are hereby incorporated by reference into this  
application in order to more fully describe the state of the  
art to which this invention pertains.

Parasympathetic regulation of the rate of heart contraction  
is exerted through the release of acetylcholine (ACh), which  
20 opens a  $K^+$  channel in the atrium and thus slows the rate of  
depolarization that leads to initiation of the action  
potential (1,2). The coupling between binding of ACh to a  
muscarinic receptor and opening of the  $K^+$  channel occurs via  
a pertussis toxin (PTX)-sensitive heterotrimeric G-protein,  
25  $G_k$  (3-5), probably belonging to the  $G_i$  family (6,7).  
Activation of this G-protein-activated  $K^+$  channel by  $G_k$  does  
not require cytoplasmic intermediates (reviewed in refs.  
8,9). However, a long-standing controversy exists as to

which G-protein subunit couples to the KG channel. Purified  $\beta\gamma$  subunit complex (10,11) and  $\alpha$  subunits of  $G_i$  family (6,7,12) activate the KG channel in cell free, inside-out patches of atrial myocytes. Activation by the  $\alpha$  subunits occurs at lower concentrations than that by  $\beta\gamma$ , but seems to be less efficient (13); the relative physiological importance of each pathway, as well as of possible involvement of the arachidonic acid pathway (14), is unclear.

- 10 A channel similar or identical to the ACh-operated KG can be activated in the atrium by adenosine (15), ATP (16), and epinephrine (17), probably also via a G-protein pathway. Furthermore, in nerve cells various 7-helix receptors such as serotonin 5HT<sub>1A</sub>,  $\delta$ -opioid, GABA<sub>B</sub>, somatostatin, etc., couple to similar K<sup>+</sup> channels, probably through direct activation by G-proteins (18-22). The similarity of the channels and of the signaling pathways in atrium and some nerve cell preparations was strengthened by the demonstration of the coupling of a neuronal 5HT<sub>1A</sub> receptor (5HT<sub>1A</sub>-R), transiently expressed in atrial myocytes, to the atrial KG (23).

By electrophysiological and pharmacological criteria, the atrial KGA channel belongs to a family of inward rectifiers that conduct K<sup>+</sup> much better in the inward than the outward direction, are blocked by extracellular Na<sup>+</sup>, Cs<sup>+</sup> and Ba<sup>2+</sup>, and are believed to possess a single-file pore with several permeant and blocking ion binding sites (24). Many inward rectifiers are not activated by transmitters or voltage but seem to be constitutively active. Inward rectification of the atrial KGA channel is due to block of K<sup>+</sup> efflux by intracellular Mg<sup>2+</sup> (25), but for some channels of this family inward rectification may not depend on Mg<sup>2+</sup> block (26,27). The molecular structures of atrial and neuronal KGs are unknown. Inwardly rectifying K<sup>+</sup> channels structurally similar to voltage-activated K<sup>+</sup> channels have been cloned from plant cells (28,29). Recently, the primary structures

of two mammalian inward rectifier channels have been elucidated by molecular cloning of their cDNAs via expression in *Xenopus* oocytes: an ATP-regulated K<sup>+</sup> channel from kidney, ROMK1 (30), and an inward rectifier from a macrophage cell line, IRKI (31). Both appear to belong to a new superfamily of K<sup>+</sup> channels, with only two transmembrane domains per subunit and a pore region homologous to that of K<sup>+</sup>, Ca<sup>2+</sup> and Na<sup>+</sup> voltage-dependent channels (see ref. 32). It has been hypothesized that the structure of G-protein activated inward rectifying K<sup>+</sup> channels should be similar to that of ROMK1 and IRK1 (31). Cloning of the atrial KGA channel and its expression in a heterologous system would be of importance not only for testing this hypothesis, but also because it will allow an as yet unexplored molecular approach to investigation of the mechanisms of direct G-protein-ion channel coupling. As a first step to cloning of the atrial KGA channel we have expressed it in *Xenopus* oocyte injected with atrial RNA and characterized the macroscopic current properties, including a preliminary characterization of G-protein coupling. We cloned the atrial KGA from a cDNA library derived from mRNA extracted from the heart of a 19 day old rat.

#### Summary of the Invention

This invention provides isolated nucleic acid molecules which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention also provides a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule.

This invention further provides a vector comprising the isolated nucleic acid molecules encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention provides a host vector system for the production of a polypeptide having the biological activity of KGA channel which comprises the above vector in a suitable host.

5 This invention also provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample which comprises: (a) isolating the nucleic acids from the sample; (b) contacting the isolated nucleic acids with the molecule  
10 of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel under the conditions permitting complex formation between the nucleic acid molecule encoding  
15 an inward rectifier, G-protein activated, potassium channel and the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the above nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel; (c) isolating  
20 the complex formed; and (d) separating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel from the complex, thereby isolating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel.

## 25 Brief Description of Figures

Figure 1. Inward currents evoked by high  $K^+$ , 5HT and ACh in RNA-injected oocytes. (A)  $I_{hK}$  and  $I_{5HT}$  in an oocyte injected with atrial RNA + 5HT1A-R RNA. Holding potential in this and all following Figures was -80mV. (B) Inward currents  
30 evoked by ACh (AcCho) and 5HT in a single oocyte in hK solution. (C) The dependence of  $I_{5HT}$  amplitude on 5HT concentration in oocytes of one frog. In each oocyte, the response to one 5HT concentration was tested. Data represent mean  $\pm$  SEM in 4-6 cells at each concentration.

- Figure 2.  $I_{hK}$  and  $I_{5HT}$  are inwardly rectifying  $K^+$  currents. (A) Currents evoked by voltage steps from the holding potential of -80 mV to voltages between -140 and 40 mV in 20 mV steps in ND96(a), hK (b), hK in the presence of 5HT (c). 5 Net  $I_{5HT}$  (d) was obtained by digital subtraction of (b) from (c). (B) Current-voltage relations of the total membrane current in a representative oocyte in NG 96 (2 mM [Kout];  $\square$ ), in 25 mM [K<sup>+</sup>out] ( $\blacklozenge$ ); in 75 mM [Kout] (o), and in hK (96 mM [Kout];  $\blacktriangle$ ). (C) Current-voltage relation of the net  $I_{5HT}$  10 in the same oocyte as in (B) in 25 mM [Kout] ( $\blacklozenge$ ), 75 mM [Kout] (o), and 96 mM [Kout] ( $\blacktriangle$ ). (D) The dependence of the reversal potentials of total membrane current ( $\blacktriangle$ ) and of  $I_{5HT}$  ( $\bullet$ ) on [Kout]. The straight lines represent least square fits to data (mean $\pm$ SEM, n=3 for each point).
- 15 Figure 3.  $Ba^{2+}$  block of  $I_{hK}$  and  $I_{5HT}$ . (A-C), records taken from the same oocyte at 10 min intervals. Between the records, the cell was bathed in ND96. 5HT concentration was 4 nM. Note that in (B) 300  $\mu$ M  $Ba^{2+}$  reduces  $I_{hK}$  and almost completely blocks  $I_{5HT}$ .  $Ba^{2+}$  and 5HT were washed out 20 simultaneously, and this resulted in an inward current "tail". (D) dose dependence of  $Ba^{2+}$  inhibition of  $I_{hK}$  in native oocytes (o),  $I_{hK}$  in RNA-injected oocytes ( $\bullet$ ),  $I_{5HT}$  in RNA-injected oocytes ( $\nabla$ ). Data are mean $\pm$ SEM, n=3 to 7 for each point.
- 25 Figure 4.  $I_{5HT}$  is mediated by activation of a G-protein. (A) The effect of PTX treatment (500 ng/ml, 20-26 h) on  $I_{hK}$  and  $I_{5HT}$ . The cells were injected with 120 ng/oocyte total atrial RNA, 11 ng/oocyte 5HT1A-R RNA, and, where indicated, with 11 ng/oocyte  $G_{i2}\alpha$  RNA. (B) GDP- $\beta$ -S injection inhibits 30  $I_{5HT}$  but not  $I_{hK}$  in an oocyte injected with atrial + 5HT1A-R RNAs. 5HT concentration was 0.4  $\mu$ M. A small outward current deflection (denoted by  $\dagger$ ) upon washout of 5HT was caused by an inadvertent perfusion of ND96 for a few seconds.

Figure 5. Nucleotide and deduced amino acid sequence encoding the inward rectifier, G-protein associated, mammalian, potassium KGA channel. Numbers in the right hand margin correlate to nucleotide position and numbers below 5 the amino acid sequence correlate with amino acid position.

#### Detailed Description of the Invention

This invention provides isolated nucleic acid molecules which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel. As used herein, the term  
10 inward rectifier, G-protein activated, mammalian, potassium KGA channel encompasses any amino acid sequence, polypeptide or protein having biological activities provided by the inward rectifier, G-protein activated, mammalian, potassium KGA channel. Furthermore the G-protein activation can be  
15 either directly or indirectly, and involve one or more G-proteins.

In one embodiment of this invention, the isolated nucleic acid molecules described hereinabove are DNA. In other embodiments of this invention, the isolated nucleic acid  
20 molecules described hereinabove are cDNA, genomic DNA or RNA. In the preferred embodiment of this invention, the isolated nucleic acid molecule is a cDNA as shown in sequence ID number 43717.APP.

This invention also encompasses DNAs and cDNAs which encode  
25 amino acid sequences which differ from those of inward rectifier, G-protein activated, mammalian, potassium KGA channel, but which should not produce functional changes in the KGA channel. This invention also encompasses nucleic acid molecules of at least 15 nucleotides capable of  
30 specifically hybridizing with the nucleic acid molecule which encode inward rectifier, G-protein activated, mammalian, potassium KGA channel. Hybridization methods are well known to those of skill in the art.

The DNA molecules of the subject invention also include DNA molecules coding for polypeptide analog, fragments or derivatives of substantially similar polypeptides which differ for naturally-occurring forms in terms of the identity of location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues are replaced by other residues and addition analog wherein one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally- occurring forms. These sequences include: the incorporation of codons preferred for expressions by selected non-mammalian host; the provision of sites for cleavage by restriction endonuclease enzymes; the addition of promoters operatively linked to enhance RNA transcription; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

The nucleic acid molecule described and claimed herein is useful for the information which it provides concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptide by a variety of recombinant techniques. The nucleic acid molecule is useful for generating new cloning and expression vectors, transformed and transfected procaryotic and eucaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expressing the inward rectifier, G-protein activated, mammalian, KGA potassium channel and related polypeptides with biological activity of the KGA channel. Capable hosts for such host vector systems may include but are not limited to a bacterial cell, an insect cell, a mammalian cell, and a Xenopus oocyte.

The isolated RNA molecule described and claimed herein is useful for the information it provides concerning the amino acid sequence of the polypeptide and as a product for synthesis of the polypeptide by injecting the RNA molecules

into *Xenopus* oocytes and culturing the oocytes under conditions that are well known to an ordinary artisan.

Moreover, the isolated nucleic acid molecules are useful for the development of probes to screen for and isolate related  
5 molecules from nucleic acid libraries other tissues, or organisms.

Inward rectifier, G-protein activated, mammalian, potassium KGA channel may be produced by a variety of vertebrate animals. In an embodiment, a rat inward rectifier, G-  
10 protein activated, mammalian, potassium KGA channel is isolated. A sequence of the DNA of rat inward rectifier, G-protein activated, mammalian, potassium KGA channel is shown in Figure 5.

The resulting plasmid, pBSIIKS(-)KGA, encoding the rat  
15 inward rectifier, G-protein activated, mammalian, potassium KGA channel was deposited on May 17, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A., under the provisions of the Budapest Treaty for the International Recognition of the  
20 Deposition of Microorganism for the Purposes of Patent Procedure. Plasmid, pBSIIKS(-)KGA, was accorded ATCC accession number 75469.

Throughout this application, references to specific nucleotides are to nucleotides present on the coding strand  
25 of the nucleic acid. The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

C = cytosine  
T = thymidine

A = adenosine  
G = guanosine

30 For the purpose of illustration only, applicants used a cDNA plasmid library derived from 19-day-old rat atrial mRNA. The DNA was synthesized from the mRNA by reverse

transcriptase using a poly(dt) primer with a XhoI overhang and was methylated. Adapters with EcoRI sites were ligated to both ends and the cDNA was digested with XhoI. It was ligated into XhoI-EcoRI-digested pBluescriptII KS(-). The library was linearized and amplified by polymerase chain reaction of the cDNA using primers that were complementary to sequences flanking the cDNA insert. cRNA was synthesized in vitro from the T7 promoter using T7 RNA polymerase. The cRNA was microinjected into *Xenopus laevis* oocytes and electrophysiological recordings under conditions described in Experimental Materials and Methods determined identification of a inward rectifier, G-protein activated, mammalian, potassium KGA channel. Fewer and fewer CDNA clones from the library were used after identification of the KGA channel until the cDNA of the inward rectifier, G-protein activated, mammalian, potassium KGA channel was isolated.

This invention provides a nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel. As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs. Nucleic acid probe technology is well known to those skill in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule which encodes inward rectifier, G-protein activated, mammalian potassium KGA channel into suitable vectors, such as plasmids, bacteriophages, or retroviral vectors followed by transforming into suitable host cells and harvesting of the DNA probes, using methods

well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.

The probes are useful for 'in situ' hybridization to locate tissues which express this gene, or for other hybridization assays for the presence of this gene or its in RNA in various biological tissues.

Vectors which comprise the isolated nucleic acid molecule described hereinabove also are provided. Suitable vectors comprise, but are not limited to, a plasmid or a virus.

10 These vectors may be transformed into a suitable host cell to form a host cell vector system for the production of a polypeptide having the biological activity of inward rectifier, G-protein activated, mammalian potassium KGA channel.

15 This invention further provides an isolated DNA or cDNA molecule described hereinabove wherein the host cell is selected from the group consisting of bacterial cells such as E. coli, yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not

20 limited to Cos cells, HeLa cells, L(tk-), and various primary mammalian cells.

This invention provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel using the probe

25 generated from the rat inward rectifier, G-protein activated, mammalian, potassium KGA channel gene. For the human, inward rectifier, G-protein activated, mammalian, potassium KGA channel, it is conceivable that the degree of homology between rat and human could be considerable.

30 Homology studies of the inward rectifier, G-protein activated, mammalian, potassium KGA channel using Genetics Computer Group Sequence Analysis Software, Version 7.2, revealed 55% identity with Human clone HHCM37 (Genbank Accession # M78731). Human heart cDNA library and human

genomic library may be used for such screening. Duplicate filters of human libraries may be screened with radio labelled probe derived from the rat inward rectifier, G-protein activated, mammalian, potassium KGA channel DNA molecule. The filters containing the human libraries will be hybridized with the probe at low stringency (Sambrook, et al 1989) and positive clones identified.

This invention provides a method to identify and purify inward rectifier, G-protein activated, potassium channels. A sample of nucleic acid molecules can be screened for nucleic acid molecules capable of supporting complex formations with an inward rectifier, G-protein activated, mammalian, KGA potassium channels nucleic acid molecule of at least 15 nucleotides under conditions well known in the art that cause complex formation between nucleic acids molecules. "Sample" as used herein includes but is not limited to genomic libraries, cDNA libraries, nucleic acid molecule extracts from tissue, or nucleic acid molecule extracts from cell culture. Conditions that pertain to complex formation between nucleic acids are well understood by an ordinary skilled artisan and include but are not limited to suboptimal temperature, ionic concentration, and size of the nucleic acid molecule. After complex formation between the nucleic acid molecule encoding the inward rectifier, G-protein activated, mammalian, KGA potassium channel and another nucleic acid, the other nucleic acid molecule can be isolated by methods known in the art.

This invention provides a method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample which comprises: (a) isolating the nucleic acids from the sample; (b) contacting the isolated nucleic acids with the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA

-12-

channel under the conditions permitting complex formation between the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel and the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel; (c) isolating the complex formed; and (d) separating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel from the complex, thereby isolating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel.

This invention further provides a method for isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof in a sample which comprises: (a) isolating the DNA from the sample; (b) denaturing the isolated DNA; (c) reannealing the denatured nucleic acids in the presence of two unique single stranded nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of the inward rectifier, G-protein associated, mammalian, potassium KGA channel that are complementary to nucleotide sequences on opposite strands of an isolated DNA molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel; (d) polymerizing the reannealed nucleic acids with DNA polymerase under conditions that allow DNA polymerization; (e) denaturing the polymerized DNA in (d); (f) repeating steps (c) through (e) for more than 10 cycles; and (g) isolating the polymerization product in step (f). The term "unique" as used herein defines a nucleic acid molecule that does not contain known genomic repeated sequences, including but not limited to Alu sequences.

This invention provides a method for isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof in a sample which comprises: (a)

isolating the DNA from the sample; (b) denaturing the isolated DNA; (c) reannealing the denatured nucleic acids in the presence of a unique single stranded nucleic acid molecules of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of the inward rectifier, G-protein associated, mammalian, potassium KGA channel that is complementary to nucleotide sequences of an isolated DNA molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel and a single stranded nucleic acid molecule encoding a known genomic repeat sequence; (d) polymerizing the reannealed nucleic acids with DNA polymerase under conditions that allow DNA polymerization; (e) denaturing the polymerized DNA in (d); (f) repeating steps (c) through (e) for more than 10 cycles; and (g) isolating the polymerization product in step (f).

This invention provides the above method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample wherein, the nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of an isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel is labelled with a detectable marker.

The invention provides the nucleic acid molecule isolated by the above method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel in a sample.

This invention provides a purified inward rectifier, G-protein activated, mammalian, potassium KGA channel.

This invention also provides the above-described purified channel having substantially the same amino acid sequence as the amino acid sequence shown in Figure 5.

This invention provides a protein encoded by the above-described isolated nucleic acid molecule.

This invention provides a method for determining whether an agent activates a KGA channel which comprises: (a) contacting the host vector system of claim 10 with the agent under conditions permitting the KGA channel conductance to be affected by known ion channel agonists or intracellular second messenger agonists; and (b) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the agent activates the KGA channel. The term "agent" as used herein describes any molecule, protein, or pharmaceutical with the capability of directly or indirectly altering ion channel conductance by affecting second messenger systems or the ion channel directly. Agents include but are not limited to serotonin, neurotropin, enkephalins, dopamine, arachidonic acid, cholera toxin, and pertussis toxin. The term "activators" as used herein defines any agent which activates a G-protein associated receptor. The term "activates" as used herein is applied to both G-protein associated receptors and ion channel conductance and in terms of G-protein associated receptors defines the state of the receptor wherein it initiates release of a G-protein subunit which in turn initiates a cellular response. In terms of the ion channel conductance "activates" defines the state of the channel wherein the channel increases conductance. The term "deactivates" as used herein defines the state of the channel wherein the channel is initiated to decrease conductance or is incapable of conductance under conditions when the channel normally conducts ions across a membrane.

This invention also provides the agent identified by the above method.

This invention provide a pharmaceutical composition comprising an amount of the above agent effective to

increase KGA conductance and a pharmaceutical acceptable carrier.

This invention provides a method for determining whether an agent deactivates KGA channel conductance which comprises:

5 (a) contacting the host vector system for the production of a polypeptide having the biological activity of KGA channel which comprises the vector comprising the nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel operatively linked to a

10 promoter of RNA transcription in a suitable host with the agent under conditions permitting the KGA channel conductance to be affected by known ion channel antagonists or intracellular second messenger system agonist; and

(b) detecting any change in KGA channel conductance, a

15 decrease in KGA channel conductance indicating that the agent deactivates the KGA channel. The term "agonist" as used herein defines an agent that initiates activation of ion channel conductance or initiates activation of a second messenger system. The term "antagonist" as used herein

20 defines an agent initiates deactivation of ion channel conductance or initiates deactivation of a second messenger system.

This invention provides agents identified by the above method for determining whether an agent deactivates KGA

25 channel conductance.

This invention provides a pharmaceutical composition comprising an amount of the above agent effective to decrease KGA channel conductance and a pharmaceutical acceptable carrier.

30 This invention provides a method for identifying in a nucleic acid sample a nucleic acid molecule encoding a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises: (a) introducing nucleic acid

molecules of claim 1 and sample to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel; (b) contacting the oocyte of step (a) with a panel of known G-protein associated receptor activators; and  
5 (c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating the identification of a G-protein associated receptor which activates the KGA channel.

This invention provides a method for isolating from a cDNA  
10 expression library a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises:

(a) isolating cDNA from a sample containing a number of clones of the cDNA expression library; (b) linearizing cDNA  
15 sample if necessary; (c) transcribing the linearized cDNA; (d) isolating the RNA from the transcribed cDNA; (e) introducing the isolated RNA and nucleic acid molecules of claim 1 into a *Xenopus* oocyte under conditions permitting expression of the KGA channel and G-protein associated  
20 receptor; (f) contacting the oocyte of step (e) with a panel of known G-protein associated receptor activators; (g) detecting change in KGA channel conductance; and (h) repeating steps (a) through (g) when an increase in KGA channel conductance is detected in step (g) using fewer cDNA  
25 clones from the sample until isolation of a single cDNA clone encoding a G-protein associated receptor which activates the KGA channel.

The invention provides a cDNA encoding the G-protein associated receptor isolated in the above method for  
30 isolating from a cDNA expression library a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

The invention provides a G-protein associated receptor isolated in the above method for isolating from a cDNA  
35 expression library a G-protein associated receptor which

activates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

This invention provides a method for testing whether a G-protein associated receptor activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises: (a) introducing a nucleic acid molecule of claim 1 and a nucleic acid molecule encoding the G-protein associated receptor to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel; (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator; and (c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the G-protein associated receptor activates the KGA channel.

This invention provides a method for identifying in a nucleic acid sample a G-protein associated receptor capable of deactivating the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising: (a) introducing nucleic acid molecule of claim 1, nucleic acid molecule of a G-protein associated receptor known to activate the KGA channel, and sample of isolated nucleic acids to a *Xenopus* oocyte under conditions permitting expression of the G-protein associated receptor that activates the KGA channel, the KGA channel and a known G-protein associated receptor; (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator and a panel of known G-protein associated receptor activators; and (c) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating the identification of an G-protein associated receptor capable of deactivating the KGA channel in the sample.

This invention provides a method for isolating from a cDNA expression library an G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises:

(a) isolating cDNA from a sample containing a number of clones of the cDNA expression library; (b) linearizing cDNA sample if necessary; (c) transcribing the linearized cDNA; (d) isolating the RNA from the transcribed cDNA; (e) 5 introducing the isolated RNA, nucleic acid molecule encoding a known G-protein associated receptor which activates the KGA channel, and nucleic acid molecules of claim 1 into a *Xenopus* oocyte under conditions permitting expression of the KGA channel and both receptors; (f) contacting the oocyte of 10 step (e) with a known G-protein associated receptor activator and a panel of known inhibitory G-protein associated activators; (g) detecting any change in KGA channel conductance,; and (h) repeating steps (a) through (g) when a decrease in KGA channel conductance is detected 15 in step (g) using fewer number of cDNA clones from the sample until isolation of a single cDNA clone encoding an inhibitory G-protein associated receptor which deactivates the KGA channel.

The invention provides a cDNA encoding the G-protein 20 associated receptor isolated by the above method for isolating from a cDNA expression library a G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel.

The invention provides a G-protein associated receptor 25 capable of deactivating the inward rectifier, G-protein activated, mammalian potassium KGA channel isolated by the above method for isolating from a cDNA expression library a G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA 30 channel.

This invention provides a method for identifying an inhibitory G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising: (a) introducing the nucleic 35 acid molecule encoding an inward rectifier, G-protein

activated, mammalian, potassium KGA channel, a G-protein associated receptor known to activate the KGA channel, and nucleic acid molecules encoding an inhibitory G-protein associated receptor to a *Xenopus* oocyte under conditions  
5 permitting expression of both the receptors and the channel;  
(b) contacting the oocyte of step (b) with a known G-protein associated receptor activator and a known inhibitory G-protein associated receptor activator; and (c) detecting any change in KGA channel conductance, a decrease in KGA channel  
10 conductance indicating that the G-protein associated receptor deactivates the KGA channel.

This invention provides an antibody directed against the purified inward rectifier, G-protein activated, mammalian, potassium KGA channel. In an embodiment, this antibody is  
15 monoclonal antibody.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the  
20 invention as described more fully in the claims which follow thereafter.

#### EXPERIMENTAL MATERIALS AND METHODS

Preparation of RNA and oocytes. Total RNA was extracted from atria and ventricles of 19-21 day old rats of both sexes  
25 using the Chomczynski-Sacchi procedure (33). Poly (A) RNA was separated on an oligo-dT cellulose column (type 3, Collaborative Biochemical Products). Ventricle poly(A) RNA was fractionated by centrifugation (18 h, 30,000 g, 4°C) on a linear 5%-25% sucrose gradient. *Xenopus laevis* oocytes  
30 were prepared as described (34) and injected with either 50-120 ng/oocyte poly(A) RNA, 120-200 ng/oocyte total RNA, or 35 ng/oocyte fractionated poly(A) RNA. In most cases, 5HT1A-R RNA (5-20 ng/oocyte) was co-injected with atrial or ventricle RNA. Final volume of the injected RNA solution

was 50 nl. The oocytes were incubated for 3-7 days in the NDE solution (ND96 (see below) containing 1.8 mM  $\text{CaCl}_2$  and supplemented with 2.5 mM Na-pyruvate and 50  $\mu\text{g/ml}$  gentamicin). Occasionally, either 2.5-5% heat-inactivated horse serum or 0.5 mM theophylline were added to the NDE solution. Incubation of oocytes in pertussis toxin (PTX; List Biochemicals) was done in NDE solution without the addition of pyruvate, serum or theophylline. cDNAs of 5HT1A receptor (see 23) and  $G_{i2}\alpha$  (a gift from M. I. Simon, Caltech) in pBluescript were linearized, and RNA was synthesized *in vitro* as described (34).

Electrophysiological recordings were performed using the two electrode voltage clamp method with the Dagan 8500 amplifier (Dagan Instruments, Minneapolis) as described (35). The oocytes were usually kept in the ND96 solution: 96 mM NaCl/2 mM KCl/1 mM  $\text{MgCl}_2$ /1 mM  $\text{CaCl}_2$ /5 mM Hepes, pH=7.5. Most measurements were done in the high  $\text{K}^+$  solution (hK): 96 mM KCl/2 mM NaCl/1 mM  $\text{MgCl}_2$ /1 mM  $\text{CaCl}_2$ /5 mM Hepes, pH=7.5. Solutions containing intermediate concentrations of  $\text{K}^+$  were made by substituting  $\text{K}^+$  for  $\text{Na}^+$ . Solution exchange and drug application were done by superfusing the cell placed in a 0.5 ml chamber. GDP- $\beta$ -S (trilithium salt; Sigma) was injected by pressure (35). Stimulation, data acquisition, and analysis were performed using pCLAMP software (Axon Instruments, Foster City, CA).

## EXPERIMENTAL RESULTS

To express the KG channel, the oocytes were injected with atrial total or poly(A) RNA. In order to avoid the possibility that a low level of expression of the muscarinic receptor will make undetectable even a well-expressed KG channel, atrial RNA was usually supplemented with mRNA coding for the serotonin-5HT1A receptor (5HT1A-R); oocytes injected with this RNA mixture will be termed RNA-injected oocytes throughout the paper. When expressed in atrial myocytes, the 5HT1A-R efficiently coupled to the KG channel

normally existing in these cells (23), and it was expected to do so in the oocytes.

Four to 5 days after RNA injection addition of 10  $\mu$ M ACh or 1-2  $\mu$ M 5HT to the ND96 bath solution did not cause any significant change in membrane current. Therefore, the effects of ACh and 5HT were tested in a high potassium (hK) solution with 96 mM  $K^+$  and 2 mM  $Na^+$ . In this solution, the  $K^+$  equilibrium potential ( $E_K$ ) is close to 0 mV, and this enables inward  $K^+$  current flow through inwardly rectifying K channels at negative holding potentials (-80 mV was routinely used in this study).

Changing ND 96 to the hK solution was accompanied by the development of an inward current that reached a steady level within 0.5-1 min ( $I_{hK}$ ; Fig 1A).  $I_{hK}$  was also observed in native (not injected with any RNA) oocytes, or in oocytes injected with 5HT1A-R RNA alone, but it was always larger in RNA-injected oocytes ( $P < 0.001$ , two-tailed t-test; Table 1).

Table 1

Inward currents evoked by high  $K^+$  and by 5HT. The entries are inward currents in nA shown as mean $\pm$ SEM (n), measured at -80mV in the hK solution. 5HT concentration ranged in 5 different experiments from 100 nM to 2  $\mu$ M.

Injected RNA	$I_{hK}$	$I_{5HT}$
None (native oocytes)	72 $\pm$ 6 (34)	0 (18)
5HT1A-R	54 $\pm$ 4 (11)	0 (12)
Atrial + 5HT1A-R	123 $\pm$ 8 (55)	290 $\pm$ 43 (55)

- 10 In RNA-injected oocytes, application of 5HT or ACh in hK solution induced an inward current ( $I_{5HT}$ ) that subsided upon washout of the transmitter (Fig. 1A, B). The response to ACh was usually smaller than to 5HT when measured in the oocytes of the same frog (Fig. 1B). Thus, in oocytes of one
- 15 frog  $I_{5HT}$  was 1102 $\pm$ 84 nA (n=6), whereas the ACh response was 382 $\pm$ 45 nA (n=6).  $I_{5HT}$  tended to decrease on repeated applications of 5HT, and this could be overcome by increasing the intervals between applications to 10 min or more, suggesting the presence of a desensitization process.
- 20  $I_{5HT}$  and an increased (in comparison with native oocytes)  $I_{hK}$  were also observed in oocytes injected with ventricle poly(A) RNA + 5HT1A-R RNA, but the  $I_{5HT}$  was about 20 times smaller than with atrial poly(A) RNA (not shown). 5HT had no effect in oocytes injected with atrial RNA without the
- 25 5HT1A-R RNA (n=4) or with 5HT1A-R RNA alone, or in native oocytes (Table 1).

The 5HT dose-response curve showed saturation at about 100 nM and a half-maximal response at about 15 nM (Fig. 1C), which is characteristic of the 5HT1 receptor class (36). A

30 similar current was evoked by a selective 5HT1A agonist, 8-OH DPAT (8-OH-2-(D1-n-(propylamino))-tetralin; data not shown).

The current-voltage (I-V) characteristic of the oocyte membrane was studied by applying voltage steps from a holding potential of -80 mV. In normal ND96, in the range -140 - -20 mV, only voltage- and time-independent "leak" currents were observed (Fig. 2a), and the I-V curve was linear (Fig. 2B). Above -20 mV, a slowly developing outward current was observed (Fig. 2A, a-c); this is known to be due to opening of a  $\text{Cl}^-$  channel activated by  $\text{Ca}^{2+}$  entry through voltage-dependent  $\text{Ca}^{2+}$  channels (37). The  $\text{Ca}^{2+}$ -activated  $\text{Cl}^-$  current was also seen in the hK solution; in addition, the total membrane current evoked by steps to -120 and up to -20 mV was larger than in ND96 (Fig. 2Ab; 2B), whereas above 0 mV there was little or no change. This suggested that most or all of  $I_{\text{hK}}$  elicited at -80 mV by the exchange of ND96 to hK solution was due to a  $\text{K}^+$  current flowing through a constitutively active inward rectifier  $\text{K}^+$  channel(s). This current showed some time-dependent inactivation at -140 mV (Fig. 2Ab) and at more negative potentials (not shown); this inactivation phenomenon was not studied further. In the presence of 5HT, the membrane currents between -140 and -20 mV were further increased (Fig. 2Ac). Net 5HT-evoked currents, obtained by digital subtraction of total membrane currents in the absence of 5HT from currents in its presence (Fig. 2Ad), showed clear inward rectification; the 5HT-activated channels conducted little or no current above  $E_{\text{K}}$  at different external  $\text{K}^+$  concentrations,  $[\text{K}_{\text{out}}]$  (Fig. 2C). The extrapolated reversal potential of  $I_{\text{5HT}}$  showed an almost perfect selectivity of the 5HT-activated channel to  $\text{K}^+$ , changing by about 58 mV per 10-fold change in  $[\text{K}_{\text{out}}]$  (Fig. 2D). The reversal potential of the total membrane current in the absence of 5HT also depended on  $[\text{K}_{\text{out}}]$  (Fig. 2B) but changed only by 24 mV per tenfold change in  $[\text{K}_{\text{out}}]$  (Fig. 2D). This does not necessarily imply poor ion selectivity of the constitutively active inward rectifier, but may reflect the relatively high contribution of  $\text{Cl}^-$  and  $\text{Na}^+$  to the resting membrane conductance (38).

Block by external  $Ba^{2+}$  is one of the characteristic features of inward rectifiers (24). In normal ND96 solution,  $Ba^{2+}$  (5  $\mu M$ -3 mM) did not cause any significant changes in resting current or conductance in native or RNA-injected oocytes at the holding potential of -80mV. In the hK solution,  $Ba^{2+}$  inhibited both  $I_{hK}$  and  $I_{5HT}$  (Fig. 3), and this was accompanied by a decrease in membrane conductance (not shown). 300  $\mu M$ ,  $Ba^{2+}$  blocked about 20% of  $I_{hK}$  but almost completely abolished  $I_{5HT}$  (Fig. 3B). The  $IC_{50}$  (half-inhibition concentration) for  $Ba^{2+}$  block of  $I_{5HT}$  was about 15  $\mu M$ , whereas  $IC_{50}$  for  $I_{hK}$  block was above 3 mM (Fig. 3D). It is noteworthy that, although the sensitivity of  $I_{hK}$  to  $Ba^{2+}$  block was similar in native and RNA-injected oocytes, the latter did appear to have a small component of  $I_{hK}$  inhibited by low doses of  $Ba^{2+}$  (Fig. 3D). This raises the possibility that the atrial  $I_{hK}$  is more sensitive to  $Ba^{2+}$  block than the oocyte's  $I_{hK}$ , or that a fraction of the highly  $Ba^{2+}$ -sensitive channels underlying  $I_{5HT}$  could be active in the absence of agonist. Note also that there was an inward current "tail" observed when  $Ba^{2+}$  and 5HT was washed out simultaneously (Fig. 3B), presumably because the rate-limiting step in deactivation of the channel proceeds more slowly than unblock from  $Ba^{2+}$ .

To estimate the size of RNA encoding the expressed inward rectifiers, ventricle poly(A) RNA (available in large amounts) was fractionated on a sucrose gradient. The size distribution of the fractions was measured by RNA gel blots probed with [ $^{32}P$ ]-labeled poly(T) (39). The RNA encoding  $I_{5HT}$  was found mainly in two size fractions covering the range between 2.5 and 5.5 kb. The peak expression of ventricle  $I_{hK}$  was in lower size fractions, in the 1.5-3 kb range (data not shown).

In atrium, the muscarinic receptor is coupled to the KG channel via a PTX-sensitive G-protein (8). Surprisingly, in RNA-injected oocytes,  $I_{5HT}$  was not affected by treatment with PTX; neither was  $I_{hK}$  (Fig. 4A). To test whether the 5HT1A

receptor couples to the  $K^+$  channel via a G-protein, the oocytes were injected with 400-800 pmole/oocyte of the non-hydrolysable analog of GDP, GDP- $\beta$ -S, that is known to inhibit the activity of PTX-sensitive as well as of PTX-insensitive G-proteins (40). In 4 cells, GDP- $\beta$ -S injection had no effect on  $I_{hK}$  ( $115 \pm 8\%$  of control) but strongly inhibited  $I_{5HT}$ , to  $4 \pm 1\%$  of control (Fig. 4B). Thus, it appears that the coupling between the 5HT $1A$  receptor and the KG channel occurs via an oocyte's endogenous PTX-insensitive G-protein.

We examined whether an overexpressed PTX-sensitive  $\alpha$  subunit of a G-protein, e.g.  $G_{i2}\alpha$ , could compete with the "native" PTX-insensitive  $\alpha$  subunit for the expressed 5HT $1A$  receptor, thus restoring the PTX sensitivity of the KG channel activation. As shown in Fig. 4A, in oocytes injected with atrial RNA plus cRNAs encoding 5HT $1A$ -R and  $G_{i2}\alpha$ , PTX inhibited  $I_{5HT}$  by about 50% ( $P < 0.01$ , two-tailed t-test), whereas  $I_{hK}$  was unaffected.

#### EXPERIMENTAL DISCUSSION

The present results demonstrate for the first time that the atrial inward rectifier  $K^+$  (KG) channel, which in the native tissue is activated by ACh via a PTX-sensitive G-protein, is expressed in oocytes injected with atrial RNA. Current through the channel can be activated by acetylcholine (ACh) or, if RNA encoding a neuronal 5HT $1A$  receptor is co-injected with atrial RNA, by serotonin (5HT). Activation of the channel probably occurs via a muscarinic ACh receptor synthesized following atrial RNA injection, rather than via the oocyte's endogenous muscarinic receptor. The latter couples to phospholipase C, and its activation induces very characteristic large transient  $Cl^-$  current responses caused by  $Ca^{2+}$  release from intracellular stores (41). Fortunately, the majority of oocyte batches lose this response after defolliculation (42), and this response was not observed in the present study. Because the ACh-evoked

currents were small in most cases, we concentrated on the study of the 5HT response; the latter was undoubtedly mediated by the introduced 5HT1A receptor, as 5HT was ineffective in oocytes not injected with 5HT1A-RNA, and the response displayed the expected pharmacological properties.

The evidence presented here indicates that, in oocytes injected with atrial and 5HT1A-R RNAs, activation of the 5HT1A receptor leads to opening of a  $K^+$  channel that bears distinctive features of an anomalous rectifier, similar to those of the atrial KG: i) it conducts inward but not outward  $K^+$  current; ii) it is blocked by low concentrations of  $Ba^{2+}$ , iii) the conductance of the channel does not depend solely on voltage but on  $(E-E_K)$ . The expression of this channel must truly be directed by atrial RNA, because: i) no hormone or transmitter-activated current of this kind is observed in native oocytes; ii) expression of 5HT1A receptor alone does not cause the appearance of such a response. Based on ventricle RNA fractionation data, the RNA encoding the 5HT-activated channel is in a broad size range between 2.5 and 5.5 kb. This is similar or somewhat smaller than the reported 4-5 kb mRNA size of some constitutively active inward rectifiers expressed in *Xenopus* oocytes (43, 44), as well as of the cloned IRK1 (5.5 kb; ref. 31) and ROMK1 (4 kb; ref. 30) channels. The properties of  $I_{5HT}$  directed by ventricle and atrial RNA are very similar, and it is reasonable to assume that they are encoded by the same RNA species.

Opening of the inward rectifier by 5HT is mediated by activation of a G-protein, as expected for the KG channel, because i) 5HT1A receptor belongs to the family of 7-helix receptors all of which act via G-proteins (40); ii)  $I_{5HT}$  was inhibited by intracellular injection of GDP- $\beta$ -S. However, the G-protein participating in this pathway was PTX-insensitive, possibly an endogenous oocyte G-protein. It is not clear why in the oocyte the channel activation pathway involves a PTX-insensitive G-protein. The atrial KG channel

normally couples to  $G_i$  (9), and there are at least two subspecies of  $G_i$  in the oocyte (45); also, some  $G_i$  may be expressed from atrial RNA. Also, in the hippocampus, the 5HT<sub>1A</sub> receptor opens a  $K^+$  channel by activating a PTX-sensitive G-protein (21). One possibility is that a vast excess of this undefined PTX-insensitive G-protein overrides the others in competition for coupling to the 5HT<sub>1A</sub> receptor. Whatever the reason for this unexpected coupling, our results show that the PTX sensitivity of the KG channel activation can be partially restored by overexpression of the  $\alpha$  subunit of  $G_i$ . Since the actual identify of the  $\alpha$  subunit does not seem to be important for activation of the expressed KG channel, these results imply that the  $\beta\gamma$  subunit complex doublet may be the activator of the channel in this case (cf. 10, 11).

Atrial and ventricle RNAs also induce an enhanced activity of an additional inward rectifier, that is active in the absence of any specific stimulation (referred to as  $I_{hk}$  in this paper).  $I_{hk}$  in atrial RNA-injected oocytes is about twice as large as in native oocytes or oocytes injected with 5HT<sub>1A</sub>-R RNA alone. This current does not appear to represent the "basal" activity of the same channel activated by 5HT or ACh because it has a much lower sensitivity to  $Ba^{2+}$  block. Moreover, the fractionation data indicates that the RNA directing the expression of  $I_{hk}$  is smaller than that encoding the KG channel. However, it is not clear whether this atrial (or ventricle) RNA encodes the channel itself or a factor that enhances the expression or the activity of a native channel. Further studies, such as expression cloning, will help to identify the messages encoding the two inward rectifiers whose expression is reported here.

References

1. Sakmann, B., Noma, A. & Trautwein, W. (1983) *Nature* 303:250-253.
- 5 2. Ijima, T., Irisawa, H. & Kameyama, M. (1985) *J. Physiol. (London)* 359:485-501.
3. Pfaffinger, P.G., Martin, J.M., Hunter, D.D., Nathanson, N.M. & Hille, B. (1985) *Nature* 317:536-538.
4. Breitweiser, G.E. & Szabo, G. (1985) *Nature* 317:538-540.
- 10 5. Kurachi, Y., Nakajima, T. & Sugimoto, T. (1986) *Am. J. Physiol.* 251:H681-H684.
6. Yatani, A., Codina, J., Brown, A.M. & Birnbaumer, L. (1987) *Science* 235:207-211.
- 15 7. Yatani, A., Mattera, R., Codina, J., Graf, R., Okane, K., Pardell, E., Iyengar, R., Brown, A.M. & Birnbaumer, L. (1988) *Nature* 336:680-682.
8. Kurachi, Y., Tung, R.T., Ito, H. & Nakajima, T. (1992) *Prog. Neurobiol.* 39:229-246.
- 20 9. Brown, A.M. & Birnbaumer, L. (1990) *A. Rev. Physiol.* 52:197-213.
10. Logothetis, D.E., Kurachi, Y., Galper, J., Neer, E.J. & Clapham, D.E. (1987) *Nature* 325:321-326.
11. Kurachi, Y., Ito, H., Sugimoto, T., Katada, T. & Ui, M. (1989) *Pflugers Arch.* 413:325-327.
- 25 12. Codina, J., Yatani, A., Grenet, D., Brown, A.M. & Birnbaumer, L. (1987) *Science* 236:442-445.
13. Ito, H., Tung, T.T., Sugimoto, T., Kobayashi, I., Takahashi, K., Katada, T., Ui, M. & Kurachi, Y. (1992) *J. Gen. Physiol.* 99:961-983.
- 30 14. Kim, D., Lewis, D.L., Graziadei, L., Neer, E.J., Barsagi, D. & Clapham, D.E. (1989) *Nature* 337:557-560.
15. Kurachi, Y., Nakajima, T., & Sugimoto, T. (1986) *Pflugers Arch.* 407:264-276.
- 35 16. Friel, D.D. & Bean, B.P. (1990) *Pflugers Arch.* 415:651-657.
17. Kurachi, Y., Ito, H., Sugimoto, T., Shimizu, T., Miki, I. & Ui, M. (1989) *Pflugers Arch.* 414:102-104.

18. Codina, J., Grenet, D., Yatani, A., Birnbaumer, L. & Brown, A.M. (1987) FEBS Letters, 216:104-106.
19. North, R.A., Williams, J.T., Suprenant, A. & Christie, M.J. (1987) Proc. Natl. Acad. Sci. USA 84:5487-5491.
- 5 20. Andrade, R., Malenka, R.C. & Nicoll, R.A. (1986) Science 234:1261-1265.
21. Andrade, R. & Nicoll, R.A. (1987) J. Physiol. 394:99-124.
- 10 22. VanDongen, A.M.J., Codina, J., Olate, J., Mattera, R., Joho, R., Birnbaumer, L. & Brown, A.M. (1988) Science 242:1433-1437.
23. Karschin, A., Ho, B.Y., Labarca, G., Elroy-Stein, O., Moss, B., Davidson, N. & Lester, H.A. (1991) Proc. Natl. Acad. Sci. USA 88:5694-5698.
- 15 24. Hille, B. (1992) *Ionic Channels of Excitable Membranes*, 2nd edition (Sinauer, Sunderland, Mass).
25. Horie, M. & Irisawa, H. (1987) Am. J. Physiol. 253:H210-H214.
- 20 26. Ciani, S., Krasne, S., Myazaki, S. & Hagiwara, S. (1978) J. Membr. Biol. 44:103-134.
27. Silver, M.R. & DeCoursey, T.E. (1990) J. Gen. Physiol. 96:109-133.
28. Sentenac H., Bonneaud N., Minet M., Lacroute F., Salmon J.-M., Gaymard F. & Grignon C. (1992) Science 256:663-665.
- 25 29. Anderson J.A., Huprikar S.S., Kochian L.V., Lucas W.J. & Gaber R.F. (1992) Proc. Natl. Acad. Sci. USA 89:3736-3740.
- 30 30. Ho, K., Nichols, C.G., Lederer, W.J., Lytton, J., Vassilev, P.M., Kanazirska, M.V. & Hebert, S.C. (1993) Nature 362:31-38.
31. Kubo, Y., Baldwin, T.J., Jan, Y.N. & Jan, L.Y. (1993) Nature 362:127-132.
32. Aldrich, R. (1993) Nature 362:107-108.
- 35 33. Chomczynski, P. & Sacchi, N. (1987) Anal. Biochem. 162:156-159.
34. Dascal, N. & Lotan, I. (1992) in *Methods in Molecular Biology*, v. 13: *Protocols in Molecular Neurobiology*, eds. Longstaff, A & Revest, P. (Humana Press, Totowa, NJ).
- 40

35. Dascal, N., Ifune, C., Hopkins, R., Snutch, T.P., Lubbert, H., Davidson, N., Simon, M., & Lester, H.A. (1986) Mol. Brain Res. 1:201-209.
- 5 36. Hoyer, D. & Schoeffer, P. (1991) J. Recept. Res. 11:197-214.
37. Barish, M.E. (1983) J. Physiol. (London) 342:309-325.
38. Dascal, N., Landau, E.M. & Lass, Y. (1984) J. Physiol. (London) 352:551-574.
- 10 39. Lubbert, H., Snutch, T.P., Dascal, N., Lester, H.A. & Davidson, N. (1987) J. Neurosci. 7:1159-1165.
40. Gilman, A.G. (1987) A. Rev. Biochem. 56:615-649.
41. Dascal, N. (1987) CRC Crit. Rev. Biochem. 22:317-387.
42. Miledi, R. & Woodward, R.M. (1989) J. Physiol. 416:601-621.
- 15 43. Lewis, D.L., Ikeda, S.R., Aryee, D. & Joho, R.H. (1991) FEBS Lett. 290:17-21.
44. Perier, F., Coulter, K.L., Radeke, C.M. & Vanderberg, C.A. (1992) J. Neurochem. 59:1971-1974.
- 20 45. Olate, J., Martinez, S., Purcell, P., Jorguera, H., Codina, J., Birnbaumer, L. & Allende, J.E. (1990) FEBS Lett. 268:27-31.

## SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANTS: Lester, Henry A., et al.
- (ii) TITLE OF INVENTION: DNA ENCODING INWARD RECTIFIER, G-PROTEIN ACTIVATED, MAMMALIAN, POTASSIUM KGA CHANNEL AND USES THEREOF
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
  - (B) STREET: 4 Embarcadero Center, Suite 3400
  - (C) CITY: San Francisco
  - (D) STATE: CA
  - (E) COUNTRY: USA
  - (F) ZIP: 94111-4187
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: PCT/US94/
  - (B) FILING DATE: 20 MAY 1994
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Trecartin, Richard F.
  - (B) REGISTRATION NUMBER: 31,801
  - (C) REFERENCE/DOCKET NUMBER: FP-59891/RFT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (415) 781-1989
  - (B) TELEFAX: (415) 398-3249

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 2076 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS  
(B) LOCATION: 32..1534

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCACGAGAA TCTGGATCTC CCCTCCGTAT T ATG TCT GCA CTC CGA AGG AAA 52  
Met Ser Ala Leu Arg Arg Lys  
1 5

TTT GGG GAC GAT TAC CAG GTA GTG ACC ACT TCG TCC AGC GGT TCG GGC 100  
Phe Gly Asp Asp Tyr Gln Val Val Thr Thr Ser Ser Ser Gly Ser Gly  
10 15 20

TTG CAG CCC CAG GGG CCA GGA CAG GGC CCA CAG CAG CAG CTT GTA CCC Leu Gln Pro Gln Gly Pro Gly Gln Gly Pro Gln Gln Gln Leu Val Pro 25 30 35	148
AAG AAG AAA CGG CAG CGG TTC GTG GAC AAG AAC GGT CGG TGC AAT GTG Lys Lys Lys Arg Gln Arg Phe Val Asp Lys Asn Gly Arg Cys Asn Val 40 45 50 55	196
CAG CAC GGC AAC CTG GGC AGC GAG ACC AGT CGC TAC CTT TCC GAC CTC Gln His Gly Asn Leu Gly Ser Glu Thr Ser Arg Tyr Leu Ser Asp Leu 60 65 70	244
TTC ACT ACC CTG GTG GAT CTC AAG TGG CGT TGG AAC CTC TTT ATC TTC Phe Thr Thr Leu Val Asp Leu Lys Trp Arg Trp Asn Leu Phe Ile Phe 75 80 85	292
ATC CTC ACC TAC ACC GTG GCC TGG CTC TTC ATG GCG TCC ATG TGG TGG Ile Leu Thr Tyr Thr Val Ala Trp Leu Phe Met Ala Ser Met Trp Trp 90 95 100	340
GTG ATC GCT TAT ACC CGG GGC GAC CTG AAC AAA GCC CAT GTC GGC AAC Val Ile Ala Tyr Thr Arg Gly Asp Leu Asn Lys Ala His Val Gly Asn 105 110 115	388
TAC ACT CCC TGT GTG GCC AAT GTC TAT AAC TTC CCC TCT GCC TTC CTT Tyr Thr Pro Cys Val Ala Asn Val Tyr Asn Phe Pro Ser Ala Phe Leu 120 125 130 135	436
TTC TTC ATC GAG ACC GAG GCC ACC ATC GGC TAT GGC TAC CGC TAC ATC Phe Phe Ile Glu Thr Glu Ala Thr Ile Gly Tyr Gly Tyr Arg Tyr Ile 140 145 150	484
ACC GAC AAG TGC CCC GAG GGC ATC ATC CTT TTC CTT TTC CAG TCC ATC Thr Asp Lys Cys Pro Glu Gly Ile Ile Leu Phe Leu Phe Gln Ser Ile 155 160 165	532
CTT GGC TCC ATC GTG GAC GCT TTC CTC ATC GGC TGC ATG TTC ATC AAG Leu Gly Ser Ile Val Asp Ala Phe Leu Ile Gly Cys Met Phe Ile Lys 170 175 180	580
ATG TCC CAG CCC AAA AAG CGC GCC GAG ACC CTC ATG TTT AGC GAG CAT Met Ser Gln Pro Lys Lys Arg Ala Glu Thr Leu Met Phe Ser Glu His 185 190 195	628
GCG GTT ATT TCC ATG AGG GAC GGA AAA CTC ACT CTC ATG TTC CGG GTG Ala Val Ile Ser Met Arg Asp Gly Lys Leu Thr Leu Met Phe Arg Val 200 205 210 215	676
GGC AAC CTG CGC AAC AGC CAC ATG GTC TCC GCG CAG ATC CGC TGC AAG Gly Asn Leu Arg Asn Ser His Met Val Ser Ala Gln Ile Arg Cys Lys 220 225 230	724
CTG CTC AAA TCT CGG CAG ACA CCT GAG GGT GAG TTT CTA CCC CTT GAC Leu Leu Lys Ser Arg Gln Thr Pro Glu Gly Glu Phe Leu Pro Leu Asp 235 240 245	772
CAA CTT GAA CTG GAT GTA GGT TTT AGT ACA GGG GCA GAT CAA CTT TTT Gln Leu Glu Leu Asp Val Gly Phe Ser Thr Gly Ala Asp Gln Leu Phe 250 255 260	820
CTT GTG TCC CCT CTC ACC ATT TGC CAC GTG ATC GAT GCC AAA AGC CCC Leu Val Ser Pro Leu Thr Ile Cys His Val Ile Asp Ala Lys Ser Pro 265 270 275	868
TTT TAT GAC CTA TCC CAG CGA AGC ATG CAA ACT GAA CAG TTC GAG GTG Phe Tyr Asp Leu Ser Gln Arg Ser Met Gln Thr Glu Gln Phe Glu Val 280 285 290 295	916



AAACATATAT ATCTAATAAA AATTGTGATG TTTTGTTCAG AAAAAAAAAA AAAAAACTCG 2074  
AG 2076

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 501 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Ala Leu Arg Arg Lys Phe Gly Asp Asp Tyr Gln Val Val Thr  
1 5 10 15  
Thr Ser Ser Ser Gly Ser Gly Leu Gln Pro Gln Gly Pro Gly Gln Gly  
20 25 30  
Pro Gln Gln Gln Leu Val Pro Lys Lys Lys Arg Gln Arg Phe Val Asp  
35 40 45  
Lys Asn Gly Arg Cys Asn Val Gln His Gly Asn Leu Gly Ser Glu Thr  
50 55 60  
Ser Arg Tyr Leu Ser Asp Leu Phe Thr Thr Leu Val Asp Leu Lys Trp  
65 70 75 80  
Arg Trp Asn Leu Phe Ile Phe Ile Leu Thr Tyr Thr Val Ala Trp Leu  
85 90 95  
Phe Met Ala Ser Met Trp Trp Val Ile Ala Tyr Thr Arg Gly Asp Leu  
100 105 110  
Asn Lys Ala His Val Gly Asn Tyr Thr Pro Cys Val Ala Asn Val Tyr  
115 120 125  
Asn Phe Pro Ser Ala Phe Leu Phe Phe Ile Glu Thr Glu Ala Thr Ile  
130 135 140  
Gly Tyr Gly Tyr Arg Tyr Ile Thr Asp Lys Cys Pro Glu Gly Ile Ile  
145 150 155 160  
Leu Phe Leu Phe Gln Ser Ile Leu Gly Ser Ile Val Asp Ala Phe Leu  
165 170 175  
Ile Gly Cys Met Phe Ile Lys Met Ser Gln Pro Lys Lys Arg Ala Glu  
180 185 190  
Thr Leu Met Phe Ser Glu His Ala Val Ile Ser Met Arg Asp Gly Lys  
195 200 205  
Leu Thr Leu Met Phe Arg Val Gly Asn Leu Arg Asn Ser His Met Val  
210 215 220  
Ser Ala Gln Ile Arg Cys Lys Leu Leu Lys Ser Arg Gln Thr Pro Glu  
225 230 235 240  
Gly Glu Phe Leu Pro Leu Asp Gln Leu Glu Leu Asp Val Gly Phe Ser  
245 250 255  
Thr Gly Ala Asp Gln Leu Phe Leu Val Ser Pro Leu Thr Ile Cys His  
260 265 270

Val Ile Asp Ala Lys Ser Pro Phe Tyr Asp Leu Ser Gln Arg Ser Met  
 275 280 285  
 Gln Thr Glu Gln Phe Glu Val Val Val Ile Leu Glu Gly Ile Val Glu  
 290 295 300  
 Thr Thr Gly Met Thr Cys Gln Ala Arg Thr Ser Tyr Thr Glu Asp Glu  
 305 310 315 320  
 Val Leu Trp Gly His Arg Phe Phe Pro Val Ile Ser Leu Glu Glu Gly  
 325 330 335  
 Phe Phe Lys Val Asp Tyr Ser Gln Phe His Ala Thr Phe Glu Val Pro  
 340 345 350  
 Thr Pro Pro Tyr Ser Val Lys Glu Gln Glu Glu Met Leu Leu Met Ser  
 355 360 365  
 Ser Pro Leu Ile Ala Pro Ala Ile Thr Asn Ser Lys Glu Arg His Asn  
 370 375 380  
 Ser Val Glu Cys Leu Asp Gly Leu Asp Asp Ile Ser Thr Lys Leu Pro  
 385 390 395 400  
 Ser Lys Leu Gln Lys Ile Thr Gly Arg Glu Asp Phe Pro Lys Lys Leu  
 405 410 415  
 Leu Arg Met Ser Ser Thr Thr Ser Glu Lys Ala Tyr Ser Leu Gly Asp  
 420 425 430  
 Leu Pro Met Lys Leu Gln Arg Ile Ser Ser Val Pro Gly Asn Ser Glu  
 435 440 445  
 Glu Lys Leu Val Ser Lys Thr Thr Lys Met Leu Ser Asp Pro Met Ser  
 450 455 460  
 Gln Ser Val Ala Asp Leu Pro Pro Lys Leu Gln Lys Met Ala Gly Gly  
 465 470 475 480  
 Pro Thr Arg Met Glu Gly Asn Leu Pro Ala Lys Leu Arg Lys Met Asn  
 485 490 495  
 Ser Asp Arg Phe Thr  
 500

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel.
- 5 2. An isolated RNA molecule of claim 1.
3. An isolated DNA molecule of claim 1.
4. An isolated cDNA molecule of claim 3.
5. A plasmid comprising the molecule of claim 1.
6. The plasmid of claim 5, designated pBSIIKS(-)KGA (ATCC  
10 Accession No. 75469).
7. A nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with the nucleic acid molecule of claim 1.
8. An isolated nucleic acid molecule of claim 1,  
15 operatively linked to a promoter of RNA transcription.
9. A vector comprising the nucleic acid molecule of claim 8.
10. A host vector system for the production of a polypeptide having the biological activity of a KGA channel  
20 which comprises the vector of claim 9 in a suitable host.
11. A host vector system of claim 10, wherein the suitable host is a bacterial cell, an insect cell, a mammalian cell, or a *Xenopus* oocyte.
12. A method for producing a polypeptide having the  
25 biological activity of a KGA channel which comprises culturing the host vector system of claim 10 under

conditions permitting production of the polypeptide and recovering the polypeptide so produced.

13. A method for isolating from a sample a nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel which comprises:
- (a) isolating nucleic acids from the sample;
  - (b) contacting the isolated nucleic acids with the molecule of claim 7, under conditions permitting formation of a complex between the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel and the molecule of claim 7;
  - (c) isolating the complex so formed; and
  - (d) separating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel from the complex, thereby isolating the nucleic acid molecule encoding an inward rectifier, G-protein activated, potassium channel.

14. A method for isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof in a sample which comprises:
- (a) isolating DNA from the sample;
  - (b) denaturing the isolated DNA;
  - (c) reannealing the denatured DNA in the presence of two unique single stranded nucleic acid molecules of claim 7 that are complementary to nucleotide sequences on opposite strands of the DNA molecule encoding an inward rectifier, G-protein activated, mammalian, potassium KGA channel;
  - (d) polymerizing the reannealed nucleic acids with DNA polymerase under conditions that allow DNA polymerization;
  - (e) denaturing the polymerized DNA of step (d);
  - (f) repeating steps (c) through (e) for 10 or more cycles; and
  - (g) isolating the polymerized DNA obtained from step (f), thereby isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof.

15. A method for isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof in a sample which comprises:

- (a) isolating DNA from the sample;
- 5 (b) denaturing the isolated DNA;
- (c) reannealing the denatured DNA in the presence of a unique single stranded nucleic acid molecule of claim 7 and a nucleic acid molecule encoding a known genomic repeat sequence;
- 10 (d) polymerizing the reannealed nucleic acids with DNA polymerase under conditions that allow DNA polymerization;
- (e) denaturing the polymerized DNA of step (d); and
- (f) repeating steps (c) through (e) for 10 or more cycles; and
- 15 (g) isolating the polymerized DNA from step (f), thereby isolating DNA encoding an inward rectifier, G-protein activated, potassium channel or a fragment thereof.

20 16. A method of claim 13, wherein the molecule of claim 7 is labelled with a detectable marker.

17. A nucleic acid molecule isolated by the method of claim 13.

25 18. A purified inward rectifier, G-protein activated, mammalian, potassium KGA channel.

19. A purified channel of claim 18, having substantially the same amino acid sequence as the amino acid sequence shown in Figure 5.

30 20. A protein encoded by the isolated nucleic acid molecule of claim 1.

21. A method for determining whether an agent activates a KGA channel which comprises:

(a) contacting the host vector system of claim 10 with the agent under conditions permitting KGA channel conductance to be affected by known ion channel agonists or intracellular second messenger agonists; and

5 (b) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the agent activates the KGA channel.

22. An agent identified by the method of claim 21.

23. A pharmaceutical composition comprising an amount of  
10 the agent of claim 22, effective to increase KGA conductance and a pharmaceutical acceptable carrier.

24. A method for determining whether an agent deactivates a KGA channel which comprises:

(a) contacting the host vector system of claim 10 with  
15 the agent under conditions permitting KGA channel conductance to be affected by known ion channel antagonists or intracellular second messenger system agonist; and

(b) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating that the  
20 agent deactivates the KGA channel.

25. An agent identified by the method of claim 24.

26. A pharmaceutical composition comprising an amount of the agent of claim 25, effective to decrease KGA channel conductance and a pharmaceutical acceptable carrier.

25 27. A method for identifying in a nucleic acid sample a nucleic acid molecule encoding a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises:

(a) introducing nucleic acid molecules of claim 1 and  
30 the nucleic acid sample to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel;

(b) contacting the oocyte of step (a) with a panel of known G-protein associated receptor activators; and

(c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating the  
5 identification of a nucleic acid molecule encoding a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel.

28. A method for isolating from a cDNA expression library  
10 a cDNA clone encoding a G-protein associated receptor which activates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises:

- (a) isolating cDNA from a sample containing a number of cDNA clones from the cDNA expression library;
- 15 (b) transcribing the isolated cDNA to produce RNA;
- (c) isolating the RNA from the transcribed cDNA;
- (e) introducing the isolated RNA and together with nucleic acid molecules of claim 1 into a *Xenopus* oocyte under conditions permitting expression of the KGA channel  
20 and G-protein associated receptor;
- (f) contacting the oocyte of step (e) with a panel of known G-protein associated receptor activators;
- (g) detecting an increase in KGA channel conductance; and
- 25 (h) repeating steps (a) through (g) using fewer cDNA clones from the sample until isolation of a single cDNA clone encoding a G-protein associated receptor which activates the KGA channel.

29. The cDNA clone isolated in claim 28.

30 30. The G-protein associated receptor encoded by the cDNA clone of claim 29.

31. A method for testing whether a G-protein associated receptor activates the inward rectifier, G-protein activated, mammalian, KGA potassium channel which comprises:

- (a) introducing a nucleic acid molecule of claim 1 and a nucleic acid molecule encoding the G-protein associated receptor to a *Xenopus* oocyte under conditions permitting expression of both the receptor and the channel;
- 5 (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator; and
- (c) detecting any change in KGA channel conductance, an increase in KGA channel conductance indicating that the G-protein associated receptor activates the KGA channel.
- 10 32. A method for identifying in a nucleic acid sample a nucleic acid molecule encoding G-protein associated receptor capable of deactivating the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising:
- (a) introducing a nucleic acid molecule of claim 1, a  
15 nucleic acid molecule encoding a G-protein associated receptor known to activate the KGA channel, and the nucleic acid sample to a *Xenopus* oocyte under conditions permitting expression of the G-protein associated receptor known to activate the KGA channel, the KGA channel and a known G-  
20 protein associated receptor;
- (b) contacting the oocyte of step (a) with a known G-protein associated receptor activator and a panel of known inhibitory G-protein associated receptor activators; and
- (c) detecting any change in KGA channel conductance,  
25 a decrease in KGA channel conductance indicating the identification of a nucleic acid molecule encoding an inhibitory G-protein associated receptor capable of deactivating the KGA channel in the sample.
33. A method for isolating from a cDNA expression library  
30 a cDNA clone encoding a G-protein associated receptor which deactivates the inward rectifier, G-protein activated, mammalian potassium KGA channel which comprises:
- (a) isolating cDNA from a sample containing a number of cDNA clones from the cDNA expression library;
- 35 (b) transcribing the isolated cDNA to produce RNA;
- (c) isolating the RNA from the transcribed cDNA;

- (e) introducing the isolated RNA, a nucleic acid molecule encoding a known G-protein associated receptor which activates the KGA channel, and the nucleic acid molecule of claim 1 into a *Xenopus* oocyte under conditions  
5 permitting expression of the KGA channel and both receptors;
- (f) contacting the oocyte of step (e) with a panel of known G-protein associated receptor activators;
- (g) detecting a decrease in KGA channel conductance;  
and
- 10 (h) repeating steps (a) through (g) using fewer cDNA clones from the sample until isolation of a single cDNA clone encoding a G-protein associated receptor which activates the KGA channel.

34. The cDNA clone encoding the G-protein associated  
15 receptor of which deactivates the inward rectifier, G-protein associated, mammalian, potassium KGA channel of claim 33.

35. The G-protein associated receptor which deactivates the  
inward rectifier, G-protein associated, mammalian, potassium  
20 KGA channel encoded by the cDNA clone of claim 34.

36. A method for identifying a nucleic acid molecule encoding a G-protein associated receptor capable of deactivating the inward rectifier, G-protein activated, mammalian KGA potassium channel comprising:

25 (a) introducing the nucleic acid molecule of claim 1, a nucleic acid molecule encoding a G-protein associated receptor known to activate the KGA channel, and nucleic acid molecules encoding an G-protein associated receptor to a *Xenopus* oocyte under conditions permitting expression of  
30 both the receptors and the channel;

(b) contacting the oocyte of step (b) with a known activator for the G-protein associated receptor which activates the KGA channel and a known activator for the other G-protein associated receptor; and

(c) detecting any change in KGA channel conductance, a decrease in KGA channel conductance indicating the identification of a nucleic acid molecule encoding the G-protein associated receptor capable of deactivating the KGA  
5 channel.

37. An antibody directed against the channel of claim 18.

38. A monoclonal antibody of claim 37.

1/9

FIGURE 1A




FIGURE 1B






FIGURE 1C



2/9

FIGURE 2A



3/9

FIGURE 2B




FIGURE 2C





FIGURE 2D



4 / 9





FIG.\_3C

FIG.\_3B

FIG.\_3A

5/9

FIGURE 3D



6/9

FIGURE 4A





FIGURE 4B



7/9.

## FIGURE 5 (1)

1	GGCA	CGA	GAA	TCT	GGA	TCT	CCC	CTC	CGT	ATT	ATG	TCT	GCA	CTC	CGA	46
1										M	S	A	L	R		5
47	AGG	AAA	TTT	GGG	GAC	GAT	TAC	CAG	GTA	GTG	ACC	ACT	TCG	TCC	AGC	91
6	R	K	F	G	D	D	Y	Q	V	V	T	T	S	S	S	20
92	GGT	TCG	GGC	TTG	CAG	CCC	CAG	GGG	CCA	GGA	CAG	GGC	CCA	CAG	CAG	136
21	G	S	G	L	Q	P	Q	G	P	G	Q	G	P	Q	Q	35
137	CAG	CTT	GTA	CCC	AAG	AAG	AAA	CGG	CAG	CGG	TTC	GTG	GAC	AAG	AAC	181
36	Q	L	V	P	K	K	K	R	Q	R	F	V	D	K	N	50
182	GGT	CGG	TGC	AAT	GTG	CAG	CAC	GGC	AAC	CTG	GGC	AGC	GAG	ACC	AGT	226
51	G	R	C	N	V	Q	H	G	N	L	G	S	E	T	S	65
227	CGC	TAC	CTT	TCC	GAC	CTC	TTC	ACT	ACC	CTG	GTG	GAT	CTC	AAG	TGG	271
66	R	Y	L	S	D	L	F	T	T	L	V	D	L	K	W	80
272	CGT	TGG	AAC	CTC	TTT	ATC	TTC	ATC	CTC	ACC	TAC	ACC	GTG	GCC	TGG	316
81	R	W	N	L	F	I	F	I	L	T	Y	T	V	A	W	95
317	CTC	TTC	ATG	GCG	TCC	ATG	TGG	TGG	GTG	ATC	GCT	TAT	ACC	CGG	GGC	361
96	L	F	M	A	S	M	W	W	V	I	A	Y	T	R	G	110
362	GAC	CTG	AAC	AAA	GCC	CAT	GTC	GGC	AAC	TAC	ACT	CCC	TGT	GTG	GCC	406
111	D	L	N	K	A	H	V	G	N	Y	T	P	C	V	A	125
407	AAT	GTC	TAT	AAC	TTC	CCC	TCT	GCC	TTC	CTT	TTC	TTC	ATC	GAG	ACC	451
126	N	V	Y	N	F	P	S	A	F	L	F	F	I	E	T	140
452	GAG	GCC	ACC	ATC	GGC	TAT	GGC	TAC	CGC	TAC	ATC	ACC	GAC	AAG	TGC	496
141	E	A	T	I	G	Y	G	Y	R	Y	I	T	D	K	C	155
497	CCC	GAG	GGC	ATC	ATC	CTT	TTC	CTT	TTC	CAG	TCC	ATC	CTT	GGC	TCC	541
156	P	E	G	I	I	L	F	L	F	Q	S	I	L	G	S	170
542	ATC	GTG	GAC	GCT	TTC	CTC	ATC	GGC	TGC	ATG	TTC	ATC	AAG	ATG	TCC	586
171	I	V	D	A	F	L	I	G	C	M	F	I	K	M	S	185
587	CAG	CCC	AAA	AAG	CGC	GCC	GAG	ACC	CTC	ATG	TTT	AGC	GAG	CAT	GCG	631
186	Q	P	K	K	R	A	E	T	L	M	F	S	E	H	A	200
632	GTT	ATT	TCC	ATG	AGG	GAC	GGA	AAA	CTC	ACT	CTC	ATG	TTC	CGG	GTG	676
201	V	I	S	M	R	D	G	K	L	T	L	M	F	R	V	215
677	GGC	AAC	CTG	CGC	AAC	AGC	CAC	ATG	GTC	TCC	GCG	CAG	ATC	CGC	TGC	721
216	G	N	L	R	N	S	H	M	V	S	A	Q	I	R	C	230
722	AAG	CTG	CTC	AAA	TCT	CGG	CAG	ACA	CCT	GAG	GGT	GAG	TTT	CTA	CCC	766
231	K	L	L	K	S	R	Q	T	P	E	G	E	F	L	P	245
767	CTT	GAC	CAA	CTT	GAA	CTG	GAT	GTA	GGT	TTT	AGT	ACA	GGG	GCA	GAT	811
246	L	D	Q	L	E	L	D	V	G	F	S	T	G	A	D	260
812	CAA	CTT	TTT	CTT	GTG	TCC	CCT	CTC	ACC	ATT	TGC	CAC	GTG	ATC	GAT	856
261	Q	L	F	L	V	S	P	L	T	I	C	H	V	I	D	275
857	GCC	AAA	AGC	CCC	TTT	TAT	GAC	CTA	TCC	CAG	CGA	AGC	ATG	CAA	ACT	901
276	A	K	S	P	F	Y	D	L	S	Q	R	S	M	Q	T	290

8/9

## FIGURE 5(2)

902	GAA	CAG	TTC	GAG	GTG	GTC	GTC	ATC	CTG	GAA	GGC	ATC	GTG	GAA	ACC	946
291	E	Q	F	E	V	V	V	I	L	E	G	I	V	E	T	305
947	ACA	GGG	ATG	ACT	TGT	CAA	GCT	CGA	ACA	TCA	TAC	ACC	GAA	GAT	GAA	991
306	T	G	M	T	C	Q	A	R	T	S	Y	T	E	D	E	320
992	GTT	CTT	TGG	GGT	CAT	CGT	TTT	TTC	CCT	GTA	ATT	TCT	TTA	GAA	GAA	1036
321	V	L	W	G	H	R	F	F	P	V	I	S	L	E	E	335
1037	GGA	TTC	TTT	AAA	GTC	GAT	TAC	TCC	CAG	TTC	CAT	GCA	ACC	TTT	GAA	1081
336	G	F	F	K	V	D	Y	S	Q	F	H	A	T	F	E	350
1082	GTC	CCC	ACC	CCT	CCG	TAC	AGT	GTG	AAA	GAG	CAG	GAA	GAA	ATG	CTT	1126
351	V	P	T	P	P	Y	S	V	K	E	Q	E	E	M	L	365
1127	CTC	ATG	TCT	TCC	CCT	TTA	ATA	GCA	CCA	GCC	ATA	ACC	AAC	AGC	AAA	1171
366	L	M	S	S	P	L	I	A	P	A	I	T	N	S	K	380
1172	GAA	AGA	CAC	AAT	TCT	GTG	GAG	TGC	TTA	GAT	GGA	CTA	GAT	GAC	ATT	1216
381	E	R	H	N	S	V	E	C	L	D	G	L	D	D	I	395
1217	AGC	ACA	AAA	CTT	CCA	TCG	AAG	CTG	CAG	AAA	ATT	ACG	GGG	AGA	GAA	1261
396	S	T	K	L	P	S	K	L	Q	K	I	T	G	R	E	410
1262	GAC	TTT	CCC	AAA	AAA	CTC	CTG	AGG	ATG	AGT	TCT	ACA	ACT	TCA	GAA	1306
411	D	F	P	K	K	L	L	R	M	S	S	T	T	S	E	425
1307	AAA	GCC	TAT	AGT	TTG	GGT	GAT	TTG	CCC	ATG	AAA	CTC	CAA	CGA	ATA	1351
426	K	A	Y	S	L	G	D	L	P	M	K	L	Q	R	I	440
1352	AGT	TCG	GTT	CCT	GGC	AAC	TCT	GAA	GAA	AAA	CTG	GTA	TCT	AAA	ACC	1396
441	S	S	V	P	G	N	S	E	E	K	L	V	S	K	T	455
1397	ACC	AAG	ATG	TTA	TCA	GAT	CCC	ATG	AGC	CAG	TCT	GTG	GCC	GAT	TTG	1441
456	T	K	M	L	S	D	P	M	S	Q	S	V	A	D	L	470
1442	CCA	CCG	AAG	CTT	CAA	AAG	ATG	GCT	GGA	GGA	CCT	ACC	AGG	ATG	GAA	1486
471	P	P	K	L	Q	K	M	A	G	G	P	T	R	M	E	485
1487	GGG	AAT	CTT	CCA	GCC	AAA	CTA	AGA	AAA	ATG	AAC	TCT	GAC	CGC	TTC	1531
486	G	N	L	P	A	K	L	R	K	M	N	S	D	R	F	500
1532	ACA	TAG	CAA	AAC	ACC	CCA	TTA	GGC	ATT	ATT	TCA	TGT	TTT	GAT	TTA	1576
501	T	*														515
1577	GTT	TTA	GTC	CAA	TAT	TTG	GCT	GAT	AAG	ATA	ATC	CTC	CCC	GGG	AAA	1621
1622	TCT	GAG	AGG	TCT	ATC	CCA	GTC	TGG	CAA	ATT	CAT	CAG	AGG	ACT	CTT	1666
1667	CAT	TGA	AGT	GTT	GTT	ACT	GTG	TTG	AAC	ATG	AGT	TAC	AAA	GGG	AGG	1711
1712	ACA	TCA	TAA	GAA	AGC	TAA	TAG	TTG	GCA	TGT	ATT	ATC	ACA	TCA	AGC	1756
1757	ATG	CAA	TAA	TGT	GCA	AAT	TTT	GCA	TTT	AGT	TTT	CTG	GCA	TGA	TTT	1801
1802	ATA	TAT	GGC	ATA	TTT	ATA	TTG	AAT	ATT	CTG	GAA	AAA	TAT	ATA	AAT	1846
1847	ATA	TAT	TTG	AAG	TGG	AGA	TAT	TCT	CCC	CAT	AAT	TTC	TAA	TAT	ATG	1891
1892	TAT	TAA	GCC	AAA	CAT	GAG	TGG	ATA	GCT	TTC	AGG	GCA	CTA	AAA	TAA	1936
1937	TAT	ACA	TGC	ATA	CAT	ACA	TAC	ATG	CAT	ATG	CAC	AGA	CAC	ATA	CAC	1981

## FIGURE 5 (3)

1982	ACA	CAT	ACT	CAT	ATA	TAT	AAA	ACA	TAC	CCA	TAC	AAA	CAT	ATA	TAT	2026
2027	CTA	ATA	AAA	ATT	GTG	ATG	TTT	TGT	TCA	AAA	AAA	AAA	AAA	AAA	AA	2070

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/05666

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : C12N 15/12, 15/63, 5/16; C07K 13/00

US CL : 536/23.5; 435/320.1, 240.2, 69.1, 91; 530/395

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 435/320.1, 240.2, 69.1, 91; 530/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y -- A	<i>Nature</i> , Volume 303, issued 19 May 1983, B. Sakmann <i>et al.</i> , "Acetylcholine activation of single muscarinic K <sup>+</sup> channels in isolated pacemaker cells of the mammalian heart", pages 250-253, especially the abstract.	18-20, 22, 23, 29 ----- 37, 38 ----- 21, 24-28, 31-36
X -- Y -- A	<i>Science</i> , Volume 235, issued 09 January 1987, A. Yatani <i>et al.</i> , "Direct Activation of Mammalian Atrial Muscarinic Potassium Channels by GTP Regulatory Protein G <sub>k</sub> ", pages 207-211, especially the abstract.	18-20, 22, 23, 29 ----- 37, 38 ----- 21, 24-28, 31-36

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 AUGUST 1994

Date of mailing of the international search report

02 SEP 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID L. FITZGERALD

Telephone No. (703) 308-0196

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y -- A	<i>Proceedings of the National Academy of Sciences of the USA</i> , Volume 88, issued July 1991, A. Karschin <i>et al.</i> , "Heterologously expressed serotonin 1A receptors couple to muscarinic K <sup>+</sup> channels in heart", pages 5694-5698, especially the abstract.	18-20, 22, 23, 29 ----- 37, 38 ----- 21, 24-28, 31-36
X,P ---- Y,P	<i>Nature</i> , Volume 364, Number 6440, issued 26 August 1993, Y. Kubo <i>et al.</i> , "Primary structure and functional expression of a rat G-protein coupled muscarinic potassium channel", pages 802-806, especially the abstract and Fig. 1.	1-12, 17-20 ----- 37, 38
X,P ---- Y,P ---- A,P	<i>Proceedings of the National Academy of Sciences of the USA</i> , Volume 90, issued November 1993, N. Dascal <i>et al.</i> , "Atrial G protein-activated K <sup>+</sup> channel: Expression cloning and molecular properties", pages 10235-10239, especially the abstract and Figs. 1A and 2.	1-12, 17-20 ----- 13-16, 37, 38 ----- 21-36
A,P	<i>Proceedings of the National Academy of Sciences of the USA</i> , Volume 90, issued July 1993, N. Dascal <i>et al.</i> , "Expression of an atrial G-protein-activated potassium channel in <i>Xenopus</i> oocytes", pages 6596-6600.	1-38
A	<i>Nature</i> , Volume 362, Number 6416, issued 11 March 1993, R. Aldrich, "Potassium channels: Advent of a new family", pages 107-108.	1-38
A	<i>Nature</i> , Volume 362, issued 04 March 1993, K. Ho <i>et al.</i> , "Cloning and expression of an inwardly rectifying ATP-regulated potassium channel", pages 31-38.	1-38
A	<i>Nature</i> , Volume 362, Number 6416, issued 11 March 1993, Y. Kubo <i>et al.</i> , "Primary structure and functional expression of a mouse inward rectifier potassium channel", pages 127-133.	1-38

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/05666

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- I. Claims 1-26, 37, and 38, directed to inward-rectifying "KGA" potassium channels, corresponding DNAs, (m)Abs specific for them, and screening assays utilizing such channels.
- II. Claims 27-36, directed to methods to identify and isolate G-protein coupled receptor cDNAs which are capable of activating or deactivating KGA channels, and to the protein products of such cDNAs.

(continued on supplemental sheet)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

Keyword databases: USPTO-APS, Dialog (Medline, Biosis, CAS, SciSearch Derwent WPI)

Search terms: potassium/K+ channel; inward rectif?; muscarinic

Sequence databases: IgSuite (searched with sequences in US priority application)

**Box II Observations where unity of invention is lacking (continued).**

The special technical feature of group I which defines an advance over the art is a recombinant KGA potassium channel. The special technical feature of group II is the activating or deactivating interaction of certain G-protein coupled cellular receptors with the KGA channel. These special technical features define distinct advances over the art because each is related to the other by application of an inventive step (i.e., neither is necessarily obvious over the other); furthermore, the (de)activating receptors of group II can be identified using naturally isolated KGA receptors and in vitro assays which do not require the use of the recombinant receptors of group I. The inventions of groups I and II are therefore not considered to be so linked as to form a single general inventive concept within the meaning of PCT Rule 13.